General Psychiatry - Articles - Page 28

Learning Objectives, Psychiatric Education, TCPR, January 2023

January 1, 2023

After reading these articles, you should be able to do the following.

RESEARCH UPDATE

Pimavanserin Improves Negative Symptoms of Schizophrenia

January 1, 2023

Brian Miller, MD, PhD, MPH. Dr. Miller, author of this educational activity, receives research support from Augusta University, the National Institute of Mental Health, the Brain and Behavior Research Foundation, and the Stanley Medical Research Institute. Relevant financial relationships listed for the author have been mitigated.

Pimavanserin (Nuplazid) is a novel antipsychotic with a narrow FDA-approval in psychosis due to Parkinson’s disease. This large randomized trial tested the drug in negative symptoms of
schizophrenia.

RESEARCH UPDATE

DBT Skills May Reduce Polypharmacy in Borderline Personality Disorder

January 1, 2023

Simon M. Dosovitz, MD

Simon M. Dosovitz, MD. Dr. Dosovitz has no financial relationships with companies related to this material.

This real-world study finds that patients with BPD are able to trade pills for skills, with substantial reductions in a controversial class of medications.

RESEARCH UPDATE

Should We Use Two Antidepressants to Treat Unipolar Depression?

January 1, 2023

Paul Riordan, MD.

Paul Riordan, MD. Dr. Riordan has no financial relationships with companies related to this material.

Antidepressant combinations come up wanting in this meta-analysis, with one possible ray of hope.

EXPERT Q&A

20 Years of The Carlat Report

January 1, 2023

Daniel Carlat, MD

Daniel Carlat, MD.

Medical Director of Inpatient Psychiatry/Chairman of Psychiatry at Melrose Wakefield Healthcare. Publisher, Carlat Publishing.

Dr. Carlat has no financial relationships with companies related to this material.

Twenty years ago, Danny Carlat walked away from industry-funded education and started The Carlat Report. Here he looks back on pivotal moments that have changed the field and shares his perspective on the controversies of today.

CLINICAL UPDATE

Viibryd Goes Generic, But Is It Worth Prescribing?

January 1, 2023

Chris Aiken, MD

Chris Aiken, MD. Editor-in-Chief of The Carlat Psychiatry Report. Practicing psychiatrist, Winston-Salem, NC. Dr. Aiken has no financial relationships with companies related to this material.

Goodbye Viibryd, hello vilazodone. This novel medication has missed the mark in a lot of trials, but it still has a narrow niche in the crowded field of antidepressants.